Could not find a ticker for this position, may be a filing error
A biotechnology company focused on rare genetic diseases, BioMarin makes enzyme-replacement and gene therapies—including VOXZOGO, the first drug approved to treat achondroplasia (dwarfism) in children—alongside treatments like VIMIZIM and NAGLAZYME used by patients with rare metabolic disorders. Founded in 1997 in Marin County, California, the company's name blends "bio" for biotechnology with "Marin," the county where it got its start. Its early founders deliberately took on rare diseases that bigger drugmakers ignored, and the company has since grown into one of the world's largest rare-disease biotechs.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -52.2K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.